Holen Sie sich die Stockscreener-App
0.00
100.00%
-1.71
Aptose Biosciences Inc Aktie (APTO) Neueste Nachrichten
Aptose Biosciences Secures Funding for Drug Development - MSN
Aptose Biosciences Reports Promising Results from TUSCANY Trial in AML - MSN
Aptose Biosciences Appoints New Independent Auditor - TipRanks
Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor - MarketScreener
Aptose Biosciences Reports Positive Early Data from TUSCANY Trial for AML Treatment - TipRanks
Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial - Yahoo Finance
Aptose Biosciences Advances Tuspetinib in AML Treatment with Promising Trial Results - MSN
Aptose Biosciences: Q2 Earnings Snapshot - Greenwich Time
Aptose Biosciences Inc. SEC 10-Q Report - TradingView
Aptose Reports Second Quarter 2025 Results - The Manila Times
When (APS) Moves Investors should Listen (APS:CA) - news.stocktradersdaily.com
Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy - The Manila Times
Aptose Biosciences Advances TUSCANY Trial with Dose Escalation - TipRanks
Aptose Cancer Drug Tuspetinib Advances to 160mg Dose After Successful Trial Results | APTOF Stock News - Stock Titan
(APS) Financial Trading Report (APS:CA) - news.stocktradersdaily.com
Where are the Opportunities in (APS) (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences Appoints Ernst & Young as New Auditor - The Globe and Mail
Aptose Selects Ernst & Young Global Limited as its New Independe - GuruFocus
Aptose Selects Ernst & Young Global Limited as its New Independent Auditor and Calls Reconvened Meeting of its Shareholders - The Manila Times
(APS) Equity Trading Insights (APS:CA) - news.stocktradersdaily.com
Aptose Receives Second Advance under the Loan Agreement with Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML - The Manila Times
About Us - FinancialContent
(APS) Comprehensive Trading Strategy Report (APS:CA) - news.stocktradersdaily.com
Delisting of Securities from The Nasdaq Stock Market - The Globe and Mail
(APS) Technical Patterns and Signals (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences Upgrades to OTCQB Market Listing - TipRanks
Aptose Announces Deferral of Interest Payment | APTOF Stock News - GuruFocus
Aptose Biosciences Defers Loan Interest Payments to Enhance Financial Flexibility - TipRanks
Aptose Biosciences Secures $8.5M Loan Agreement - TipRanks
(APS) Investment Performance Report (APS:CA) - news.stocktradersdaily.com
(APS) Equity Market Report (APS:CA) - news.stocktradersdaily.com
Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML - Yahoo Finance
Stocks In Play: Aptose Biosciences Inc. - Barchart.com
Aptose Provides Corporate Updates - The Manila Times
Aptose Provides Corporate Updates | APTOF Stock News - GuruFocus
Aptose CEO props up biotech's finances to prevent company from going bust - Fierce Biotech
(APS) Investment Analysis and Advice (APS:CA) - news.stocktradersdaily.com
Aptose Presents Safety, Response, and MRD Clinical Data from TUS - GuruFocus
Aptose reports promising data from TUS+VEN+AZA therapy for AML By Investing.com - Investing.com South Africa
Aptose reports promising data from TUS+VEN+AZA therapy for AML - Investing.com Canada
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress - The Manila Times
APTOAptose Announces Reverse Share Split - Revista ADVFN
(APS) Technical Pivots with Risk Controls (APS:CA) - news.stocktradersdaily.com
0.98%
8.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):